Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Epizyme, Inc. (EPZM) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Epizyme, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1571498.
Total stock buying since 2014: $152,449,594.
Total stock sales since 2014: $68,850,528.
Total stock option exercises since 2014: $7,132,028.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2022 | 22,666,667 | $34,000,000 | 12,138 | $17,404 | 2,397,500 | $3,344,699 |
| 2021 | 62,717 | $497,205 | 34,367 | $333,399 | 0 | $0 |
| 2020 | 67,019 | $1,054,514 | 170,444 | $3,544,028 | 141,558 | $1,369,352 |
| 2019 | 0 | $0 | 163,045 | $2,093,550 | 0 | $0 |
| 2018 | 416,667 | $3,750,003 | 72,264 | $1,222,201 | 72,264 | $692,289 |
| 2017 | 200,000 | $3,050,000 | 108,550 | $1,696,370 | 122,174 | $849,075 |
| 2016 | 12,222,220 | $109,999,980 | 36,692 | $393,408 | 102,746 | $141,154 |
| 2015 | 4,322 | $69,668 | 245,589 | $5,129,001 | 245,589 | $131,212 |
| 2014 | 1,400 | $28,224 | 1,670,145 | $54,421,167 | 562,671 | $604,247 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2022-08 | 0 | $0 | 0 | $0 | 2,397,500 | $3,344,699 |
| 2022-04 | 0 | $0 | 2,741 | $2,466 | 0 | $0 |
| 2022-02 | 0 | $0 | 6,475 | $9,036 | 0 | $0 |
| 2022-01 | 22,666,667 | $34,000,000 | 2,922 | $5,902 | 0 | $0 |
| 2021-12 | 0 | $0 | 1,780 | $5,215 | 0 | $0 |
| 2021-04 | 0 | $0 | 2,029 | $17,855 | 0 | $0 |
| 2021-03 | 62,717 | $497,205 | 10,328 | $81,074 | 0 | $0 |
| 2021-02 | 0 | $0 | 7,818 | $87,636 | 0 | $0 |
| 2021-01 | 0 | $0 | 12,412 | $141,619 | 0 | $0 |
| 2020-12 | 0 | $0 | 2,522 | $34,147 | 0 | $0 |
| 2020-11 | 5,000 | $60,350 | 0 | $0 | 0 | $0 |
| 2020-09 | 0 | $0 | 543 | $6,993 | 0 | $0 |
| 2020-08 | 0 | $0 | 0 | $0 | 7,055 | $0 |
| 2020-06 | 62,019 | $994,164 | 143,431 | $3,019,519 | 122,003 | $1,252,727 |
| 2020-03 | 0 | $0 | 8,222 | $132,503 | 12,500 | $116,625 |
| 2020-01 | 0 | $0 | 15,726 | $350,866 | 0 | $0 |
| 2019-09 | 0 | $0 | 971 | $12,399 | 0 | $0 |
| 2019-06 | 0 | $0 | 162,074 | $2,081,151 | 0 | $0 |
| 2018-10 | 416,667 | $3,750,003 | 0 | $0 | 0 | $0 |
| 2018-02 | 0 | $0 | 72,264 | $1,222,201 | 72,264 | $692,289 |
| 2017-10 | 0 | $0 | 15,000 | $246,585 | 15,000 | $134,700 |
| 2017-09 | 200,000 | $3,050,000 | 15,000 | $252,075 | 15,000 | $134,700 |
| 2017-08 | 0 | $0 | 15,000 | $235,260 | 17,460 | $134,700 |
| 2017-07 | 0 | $0 | 15,000 | $201,570 | 17,459 | $134,700 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-08-09 | Beaulieu Joseph (See Remarks) | Option Ex | 300,000 | 1.39 | 416,999 |
| 2022-08-09 | Agarwal Shefali (Other) | Option Ex | 500,000 | 1.39 | 695,000 |
| 2022-08-09 | Kutok Jeffery (Chief Scientific Officer) | Option Ex | 380,000 | 1.39 | 528,200 |
| 2022-08-09 | Bogle Grant C. (See Remarks) | Option Ex | 1,217,500 | 1.40 | 1,704,500 |
| 2022-04-11 | Kutok Jeffery (Chief Scientific Officer) | Sale | 2,741 | .90 | 2,466 |
| 2022-02-07 | Beaulieu Joseph (Corporate Controller) | Sale | 222 | 1.50 | 333 |
| 2022-02-07 | Agarwal Shefali (See Remarks) | Sale | 1,058 | 1.50 | 1,587 |
| 2022-02-02 | Agarwal Shefali (See Remarks) | Sale | 2,639 | 1.37 | 3,615 |
| 2022-02-02 | Kutok Jeffery (Chief Scientific Officer) | Sale | 2,556 | 1.37 | 3,501 |
| 2022-01-31 | Rpi Finance Trust (10% Owner) | Buy | 22,666,667 | 1.50 | 34,000,000 |
| 2022-01-26 | Agarwal Shefali (See Remarks) | Sale | 2,922 | 2.02 | 5,902 |
| 2021-12-06 | Agarwal Shefali (See Remarks) | Sale | 1,780 | 2.93 | 5,215 |
| 2021-04-05 | Kutok Jeffery (Chief Scientific Officer) | Sale | 2,029 | 8.80 | 17,855 |
| 2021-03-26 | Mott David M (Director) | Buy | 34,486 | 7.88 | 271,922 |
| 2021-03-25 | Bazemore Robert B (President & CEO) | Sale | 10,328 | 7.85 | 81,074 |
| 2021-03-25 | Mott David M (Director) | Buy | 28,231 | 7.98 | 225,283 |
| 2021-02-04 | Vakiener Victoria (Chief Commercial Officer) | Sale | 817 | 11.21 | 9,158 |
| 2021-02-04 | Beaulieu Joseph (Corporate Controller) | Sale | 227 | 11.21 | 2,544 |
| 2021-02-04 | Agarwal Shefali (Chief Medical Officer) | Sale | 969 | 11.21 | 10,862 |
| 2021-02-04 | Tombesi Paolo (Chief Financial Officer) | Sale | 1,021 | 11.21 | 11,445 |
| 2021-02-04 | Ros Matthew (See Remarks) | Sale | 894 | 11.21 | 10,021 |
| 2021-02-04 | Bazemore Robert B (President & CEO) | Sale | 3,890 | 11.21 | 43,606 |
| 2021-01-25 | Vakiener Victoria (Chief Commercial Officer) | Sale | 599 | 11.41 | 6,834 |
| 2021-01-25 | Agarwal Shefali (Chief Medical Officer) | Sale | 2,872 | 11.41 | 32,769 |
| 2021-01-25 | Ros Matthew (See Remarks) | Sale | 2,872 | 11.41 | 32,769 |
| 2021-01-25 | Bazemore Robert B (President & CEO) | Sale | 6,069 | 11.41 | 69,247 |
| 2020-12-03 | Agarwal Shefali (Chief Medical Officer) | Sale | 2,522 | 13.54 | 34,147 |
| 2020-11-11 | Goldfischer Carl (Director) | Buy | 5,000 | 12.07 | 60,350 |
| 2020-09-02 | Beaulieu Joseph (Corporate Controller) | Sale | 543 | 12.88 | 6,993 |
| 2020-08-19 | Tombesi Paolo (Chief Financial Officer) | Option Ex | 7,055 | .00 | 0 |
| 2020-06-26 | Beaulieu Joseph (Corporate Controller) | Sale | 317 | 16.15 | 5,119 |
| 2020-06-26 | Agarwal Shefali (Chief Medical Officer) | Sale | 1,805 | 16.15 | 29,150 |
| 2020-06-26 | Tombesi Paolo (Chief Financial Officer) | Sale | 1,805 | 16.15 | 29,150 |
| 2020-06-26 | Ros Matthew (See Remarks) | Sale | 2,728 | 16.15 | 44,057 |
| 2020-06-26 | Bazemore Robert B (President & CEO) | Sale | 4,773 | 16.15 | 77,083 |
| 2020-06-26 | Mott David M (Director) | Buy | 62,019 | 16.03 | 994,164 |
| 2020-06-18 | Ros Matthew (See Remarks) | Sale | 112,003 | 21.38 | 2,394,960 |
| 2020-06-18 | Ros Matthew (See Remarks) | Option Ex | 112,003 | 10.38 | 1,162,927 |
| 2020-06-18 | Bazemore Robert B (President & CEO) | Sale | 20,000 | 22.00 | 440,000 |
| 2020-06-18 | Bazemore Robert B (President & CEO) | Option Ex | 10,000 | 8.98 | 89,800 |
| 2020-03-25 | Beaulieu Joseph (Corporate Controller) | Sale | 212 | 15.28 | 3,239 |
| 2020-03-25 | Agarwal Shefali (Chief Medical Officer) | Sale | 1,243 | 15.28 | 18,993 |
| 2020-03-25 | Tombesi Paolo (Chief Financial Officer) | Sale | 1,243 | 15.28 | 18,993 |
| 2020-03-25 | Ros Matthew (See Remarks) | Sale | 1,243 | 15.28 | 18,993 |
| 2020-03-25 | Bazemore Robert B (President & CEO) | Sale | 3,285 | 15.28 | 50,194 |
| 2020-03-16 | Allen Andrew R (Director) | Option Ex | 12,500 | 9.33 | 116,625 |
| 2020-03-03 | Beaulieu Joseph (Corporate Controller) | Sale | 996 | 22.18 | 22,091 |
| 2020-01-27 | Agarwal Shefali (Chief Medical Officer) | Sale | 2,630 | 20.44 | 53,757 |
| 2020-01-27 | Bazemore Robert B (President & CEO) | Sale | 6,074 | 20.44 | 124,152 |
| 2020-01-24 | Beaulieu Joseph (Corporate Controller) | Sale | 330 | 24.63 | 8,127 |
| 2020-01-24 | Agarwal Shefali (Chief Medical Officer) | Sale | 1,843 | 24.64 | 45,411 |
| 2020-01-24 | Ros Matthew (See Remarks) | Sale | 1,847 | 24.64 | 45,510 |
| 2020-01-24 | Bazemore Robert B (President & CEO) | Sale | 3,002 | 24.62 | 73,909 |
| 2019-09-03 | Beaulieu Joseph (Corporate Controller) | Sale | 971 | 12.77 | 12,399 |
| 2019-06-27 | Mott David M (Director) | Sale | 52,473 | 12.43 | 652,134 |
| 2019-06-26 | Mott David M (Director) | Sale | 52,472 | 12.85 | 674,160 |
| 2019-06-25 | Mott David M (Director) | Sale | 52,472 | 13.31 | 698,664 |
| 2019-06-14 | Agarwal Shefali (Chief Medical Officer) | Sale | 1,195 | 11.97 | 14,304 |
| 2019-06-13 | Beaulieu Joseph (Corporate Controller) | Sale | 203 | 12.10 | 2,456 |
| 2019-06-13 | Ros Matthew (See Remarks) | Sale | 1,185 | 12.10 | 14,338 |
| 2019-06-13 | Bazemore Robert B (President & CEO) | Sale | 2,074 | 12.10 | 25,095 |
| 2018-10-05 | Mott David M (Director) | Buy | 416,667 | 9.00 | 3,750,003 |
| 2018-02-05 | Ros Matthew (Chief Operating Officer) | Sale | 72,264 | 16.91 | 1,222,201 |
| 2018-02-05 | Ros Matthew (Chief Operating Officer) | Option Ex | 72,264 | 9.58 | 692,289 |
| 2017-10-24 | Ho Peter Tai-ching (Chief Development Officer) | Sale | 15,000 | 16.44 | 246,585 |
| 2017-10-24 | Ho Peter Tai-ching (Chief Development Officer) | Option Ex | 15,000 | 8.98 | 134,700 |
| 2017-09-25 | Ho Peter Tai-ching (Chief Development Officer) | Sale | 15,000 | 16.80 | 252,075 |
| 2017-09-25 | Ho Peter Tai-ching (Chief Development Officer) | Option Ex | 15,000 | 8.98 | 134,700 |
| 2017-09-18 | Mott David M (Director) | Buy | 200,000 | 15.25 | 3,050,000 |
| 2017-08-24 | Ho Peter Tai-ching (Chief Development Officer) | Sale | 15,000 | 15.68 | 235,260 |
| 2017-08-24 | Ho Peter Tai-ching (Chief Development Officer) | Option Ex | 15,000 | 8.98 | 134,700 |
| 2017-08-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,460 | .00 | 0 |
| 2017-07-24 | Ho Peter Tai-ching (Chief Development Officer) | Sale | 15,000 | 13.44 | 201,570 |
| 2017-07-24 | Ho Peter Tai-ching (Chief Development Officer) | Option Ex | 15,000 | 8.98 | 134,700 |
| 2017-07-10 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2017-06-30 | Singer Andrew E. (EVP & CFO) | Sale | 3,024 | 15.50 | 46,872 |
| 2017-06-26 | Ho Peter Tai-ching (Chief Development Officer) | Sale | 15,000 | 14.87 | 223,110 |
| 2017-06-26 | Ho Peter Tai-ching (Chief Development Officer) | Option Ex | 15,000 | 8.98 | 134,700 |
| 2017-06-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2017-06-06 | Copeland Robert A (President of Research and CSO) | Sale | 2,500 | 13.45 | 33,625 |
| 2017-06-06 | Copeland Robert A (President of Research and CSO) | Option Ex | 2,500 | 3.54 | 8,850 |
| 2017-05-25 | Ho Peter Tai-ching (Chief Development Officer) | Sale | 15,000 | 16.11 | 241,665 |
| 2017-05-25 | Ho Peter Tai-ching (Chief Development Officer) | Option Ex | 15,000 | 8.98 | 134,700 |
| 2017-05-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,460 | .00 | 0 |
| 2017-05-02 | Copeland Robert A (President of Research and CSO) | Sale | 5,000 | 17.44 | 87,215 |
| 2017-05-02 | Copeland Robert A (President of Research and CSO) | Option Ex | 5,000 | 3.54 | 17,700 |
| 2017-04-10 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2017-04-04 | Copeland Robert A (President of Research and CSO) | Sale | 5,000 | 16.36 | 81,805 |
| 2017-04-04 | Copeland Robert A (President of Research and CSO) | Option Ex | 5,000 | 2.87 | 14,325 |
| 2017-03-31 | Singer Andrew E. (EVP & CFO) | Sale | 2,013 | 17.09 | 34,394 |
| 2017-03-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2017-02-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2017-01-09 | Singer Andrew E. (EVP & CFO) | Sale | 1,013 | 12.04 | 12,194 |
| 2017-01-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2016-12-09 | Singer Andrew E. (EVP & CFO) | Sale | 1,013 | 11.03 | 11,172 |
| 2016-12-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2016-12-08 | Ho Peter Tai-ching (Chief Development Officer) | Sale | 200 | 10.89 | 2,178 |
| 2016-11-09 | Singer Andrew E. (EVP & CFO) | Sale | 1,013 | 10.40 | 10,535 |
| 2016-11-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,460 | .00 | 0 |
| 2016-10-10 | Singer Andrew E. (EVP & CFO) | Sale | 1,013 | 9.72 | 9,848 |
| 2016-10-10 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2016-09-09 | Singer Andrew E. (EVP & CFO) | Sale | 1,013 | 7.55 | 7,651 |
| 2016-09-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2016-08-09 | Singer Andrew E. (EVP & CFO) | Sale | 1,013 | 9.05 | 9,165 |
| 2016-08-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,460 | .00 | 0 |
| 2016-08-01 | Copeland Robert A (President of Research and CSO) | Sale | 4,000 | 10.37 | 41,492 |
| 2016-08-01 | Copeland Robert A (President of Research and CSO) | Option Ex | 4,000 | 2.19 | 8,760 |
| 2016-07-11 | Singer Andrew E. (EVP & CFO) | Sale | 1,013 | 10.36 | 10,493 |
| 2016-07-11 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2016-07-05 | Copeland Robert A (President of Research and CSO) | Sale | 4,000 | 10.03 | 40,128 |
| 2016-07-05 | Copeland Robert A (President of Research and CSO) | Option Ex | 4,000 | 2.19 | 8,760 |
| 2016-06-09 | Singer Andrew E. (EVP & CFO) | Sale | 1,013 | 12.49 | 12,655 |
| 2016-06-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2016-06-01 | Copeland Robert A (President of Research and CSO) | Option Ex | 31,538 | 3.54 | 111,644 |
| 2016-05-09 | Singer Andrew E. (EVP & CFO) | Sale | 1,013 | 9.94 | 10,070 |
| 2016-05-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,460 | .00 | 0 |
| 2016-04-12 | Singer Andrew E. (EVP & CFO) | Sale | 346 | 12.14 | 4,200 |
| 2016-04-11 | Singer Andrew E. (EVP & CFO) | Sale | 1,680 | 12.48 | 20,966 |
| 2016-04-11 | Singer Andrew E. (EVP & CFO) | Option Ex | 4,918 | .00 | 0 |
| 2016-03-09 | Singer Andrew E. (EVP & CFO) | Sale | 1,006 | 9.05 | 9,104 |
| 2016-03-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 2,459 | .00 | 0 |
| 2016-02-10 | Singer Andrew E. (EVP & CFO) | Sale | 12,158 | 9.54 | 115,987 |
| 2016-02-09 | Singer Andrew E. (EVP & CFO) | Option Ex | 29,512 | .00 | 0 |
| 2016-01-12 | Viswanathan Ravi (10% Owner) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-12 | Bay City Capital Management V Llc (10% Owner) | Buy | 555,555 | 9.00 | 4,999,995 |
| 2016-01-12 | Nea 13 Gp, Ltd (10% Owner) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-12 | Weller Harry R (10% Owner) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-12 | Baskett Forest (10% Owner) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-12 | Kolluri Krishna Kittu (10% Owner) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-12 | Sandell Scott D (10% Owner) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-12 | Kerins Patrick J (10% Owner) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-12 | Mott David M (Director) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-12 | Barrett M James (10% Owner) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-12 | Goldfischer Carl (Director) | Buy | 555,555 | 9.00 | 4,999,995 |
| 2016-01-12 | Barris Peter J (10% Owner) | Buy | 1,111,111 | 9.00 | 9,999,999 |
| 2016-01-04 | Copeland Robert A (President of Research and CSO) | Sale | 4,185 | 15.57 | 65,181 |
| 2016-01-04 | Copeland Robert A (President of Research and CSO) | Option Ex | 4,185 | 2.87 | 11,990 |
| 2015-12-30 | Gould Robert J (Director) | Sale | 11,805 | 18.02 | 212,714 |
| 2015-12-30 | Gould Robert J (Director) | Option Ex | 11,805 | .51 | 6,020 |
| 2015-12-29 | Gould Robert J (Director) | Sale | 20,303 | 18.01 | 365,616 |
| 2015-12-29 | Gould Robert J (Director) | Option Ex | 20,303 | .51 | 10,354 |
| 2015-12-09 | Ho Peter Tai-ching (Chief Development Officer) | Buy | 1,000 | 14.69 | 14,690 |
| 2015-12-07 | Copeland Robert A (President of Research and CSO) | Sale | 4,185 | 13.82 | 57,845 |
| 2015-12-07 | Copeland Robert A (President of Research and CSO) | Option Ex | 4,185 | 1.40 | 5,838 |
| 2015-11-09 | Copeland Robert A (President of Research and CSO) | Sale | 4,185 | 16.26 | 68,060 |
| 2015-11-09 | Copeland Robert A (President of Research and CSO) | Option Ex | 4,185 | .60 | 2,511 |
| 2015-10-05 | Copeland Robert A (President of Research and CSO) | Sale | 4,185 | 14.43 | 60,381 |
| 2015-10-05 | Copeland Robert A (President of Research and CSO) | Option Ex | 4,185 | .60 | 2,511 |
| 2015-09-08 | Gould Robert J (President & CEO) | Sale | 60,000 | 19.56 | 1,173,600 |
| 2015-09-08 | Gould Robert J (President & CEO) | Option Ex | 60,000 | .51 | 30,600 |
| 2015-09-08 | Copeland Robert A (President of Research and CSO) | Sale | 4,185 | 19.57 | 81,921 |
| 2015-09-08 | Copeland Robert A (President of Research and CSO) | Option Ex | 4,185 | .60 | 2,511 |
| 2015-08-31 | Ho Peter Tai-ching (Chief Development Officer) | Buy | 522 | 17.00 | 8,874 |
| 2015-08-20 | Ho Peter Tai-ching (Chief Development Officer) | Buy | 2,000 | 16.51 | 33,020 |
| 2015-08-03 | Gould Robert J (President & CEO) | Sale | 60,000 | 22.17 | 1,330,200 |
| 2015-08-03 | Gould Robert J (President & CEO) | Option Ex | 60,000 | .51 | 30,600 |
| 2015-08-03 | Copeland Robert A (President of Research and CSO) | Sale | 8,370 | 22.19 | 185,730 |
| 2015-08-03 | Copeland Robert A (President of Research and CSO) | Option Ex | 8,370 | .60 | 5,022 |
| 2015-07-06 | Gould Robert J (President & CEO) | Sale | 60,000 | 23.36 | 1,401,540 |
| 2015-07-06 | Gould Robert J (President & CEO) | Option Ex | 60,000 | .51 | 30,600 |
| 2015-07-06 | Copeland Robert A (President of Research and CSO) | Sale | 8,371 | 22.86 | 191,394 |
| 2015-07-06 | Copeland Robert A (President of Research and CSO) | Option Ex | 8,371 | .56 | 4,645 |
| 2015-05-05 | Ho Peter Tai-ching (Chief Development Officer) | Buy | 800 | 16.36 | 13,084 |
| 2014-12-16 | Ho Peter Tai-ching (Chief Development Officer) | Buy | 400 | 17.63 | 7,052 |
| 2014-12-02 | Ho Peter Tai-ching (Chief Development Officer) | Buy | 1,000 | 21.17 | 21,172 |
| 2014-11-17 | Copeland Robert A (EVP and CSO) | Sale | 20,000 | 22.68 | 453,640 |
| 2014-11-17 | Copeland Robert A (EVP and CSO) | Option Ex | 20,000 | 2.19 | 43,800 |
| 2014-11-03 | Garbacz Stephen (Principal Accounting Officer) | Sale | 868 | 26.44 | 22,949 |
| 2014-11-03 | Garbacz Stephen (Principal Accounting Officer) | Option Ex | 868 | 2.19 | 1,900 |
| 2014-11-03 | Gould Robert J (President & CEO) | Sale | 30,000 | 25.62 | 768,510 |
| 2014-11-03 | Gould Robert J (President & CEO) | Option Ex | 30,000 | .51 | 15,300 |
| 2014-11-03 | Copeland Robert A (EVP and CSO) | Sale | 20,000 | 25.72 | 514,320 |
| 2014-11-03 | Copeland Robert A (EVP and CSO) | Option Ex | 20,000 | 1.40 | 27,900 |
| 2014-10-23 | Garbacz Stephen (Principal Accounting Officer) | Sale | 535 | 30.00 | 16,050 |
| 2014-10-23 | Garbacz Stephen (Principal Accounting Officer) | Option Ex | 535 | 3.54 | 1,893 |
| 2014-10-15 | Hedrick Eric (Chief Medical Officer) | Sale | 2,000 | 23.38 | 46,760 |
| 2014-10-15 | Hedrick Eric (Chief Medical Officer) | Option Ex | 2,000 | 2.19 | 4,380 |
| 2014-10-07 | Copeland Robert A (EVP and CSO) | Sale | 20,000 | 27.30 | 545,980 |
| 2014-10-07 | Copeland Robert A (EVP and CSO) | Option Ex | 20,000 | .60 | 12,000 |
| 2014-10-01 | Garbacz Stephen (Principal Accounting Officer) | Sale | 868 | 27.06 | 23,488 |
| 2014-10-01 | Garbacz Stephen (Principal Accounting Officer) | Option Ex | 868 | 2.19 | 1,900 |
| 2014-10-01 | Gould Robert J (President & CEO) | Sale | 30,000 | 26.66 | 799,860 |
| 2014-10-01 | Gould Robert J (President & CEO) | Option Ex | 30,000 | .51 | 15,300 |
| 2014-09-22 | Copeland Robert A (EVP and CSO) | Sale | 20,000 | 25.55 | 511,000 |
| 2014-09-22 | Copeland Robert A (EVP and CSO) | Option Ex | 20,000 | .60 | 12,000 |
| 2014-09-22 | Rhodes Jason P (President, CFO and Treasurer) | Option Ex | 44,000 | .51 | 22,440 |
| 2014-09-15 | Hedrick Eric (Chief Medical Officer) | Sale | 2,000 | 28.67 | 57,340 |
| 2014-09-15 | Hedrick Eric (Chief Medical Officer) | Option Ex | 2,000 | 2.19 | 4,380 |
| 2014-09-04 | Goldfischer Carl (Director) | Sale | 4,000 | 35.14 | 140,560 |
| 2014-09-02 | Gould Robert J (CEO) | Sale | 30,000 | 33.60 | 1,007,940 |
| 2014-09-02 | Gould Robert J (CEO) | Option Ex | 30,000 | .51 | 15,300 |
| 2014-09-02 | Rhodes Jason P (President, CFO and Treasurer) | Sale | 30,000 | 33.63 | 1,008,869 |
| 2014-09-02 | Rhodes Jason P (President, CFO and Treasurer) | Option Ex | 42,000 | 2.07 | 86,940 |
| 2014-08-26 | Bay City Capital Management V Llc (10% Owner) | Sale | 200,000 | 35.14 | 7,027,800 |
| 2014-08-26 | Goldfischer Carl (Director) | Sale | 200,000 | 35.14 | 7,027,800 |
| 2014-08-25 | Bay City Capital Management V Llc (10% Owner) | Sale | 200,000 | 35.77 | 7,153,600 |
| 2014-08-25 | Goldfischer Carl (Director) | Sale | 200,000 | 35.77 | 7,153,600 |
| 2014-08-22 | Bay City Capital Management V Llc (10% Owner) | Sale | 128,000 | 32.46 | 4,154,752 |
| 2014-08-22 | Goldfischer Carl (Director) | Sale | 128,000 | 32.46 | 4,154,752 |
| 2014-08-21 | Bay City Capital Management V Llc (10% Owner) | Sale | 38,666 | 33.03 | 1,277,331 |
| 2014-08-21 | Goldfischer Carl (Director) | Sale | 38,666 | 33.03 | 1,277,331 |
| 2014-08-18 | Copeland Robert A (EVP and CSO) | Sale | 10,830 | 36.22 | 392,273 |
| 2014-08-18 | Viswanathan Ravi (10% Owner) | Sale | 433 | 35.56 | 15,396 |
| 2014-08-15 | Hedrick Eric (Chief Medical Officer) | Sale | 2,000 | 38.60 | 77,200 |
| 2014-08-15 | Hedrick Eric (Chief Medical Officer) | Option Ex | 2,000 | 2.19 | 4,380 |
| 2014-08-15 | Drant Ryan D (10% Owner) | Sale | 4,061 | 36.70 | 149,046 |
| 2014-08-15 | Baskett Forest (10% Owner) | Sale | 3,970 | 36.81 | 146,119 |
| 2014-08-15 | Kolluri Krishna Kittu (10% Owner) | Sale | 1,302 | 36.57 | 47,614 |
| 2014-08-15 | Sandell Scott D (10% Owner) | Sale | 3,411 | 36.70 | 125,166 |
| 2014-08-15 | Barrett M James (10% Owner) | Sale | 4,061 | 36.25 | 147,195 |
| 2014-08-15 | Barris Peter J (10% Owner) | Sale | 3,411 | 36.70 | 125,166 |
| 2014-08-04 | Copeland Robert A (EVP and CSO) | Sale | 20,000 | 29.48 | 589,600 |
| 2014-08-04 | Copeland Robert A (EVP and CSO) | Option Ex | 20,000 | .60 | 12,000 |
| 2014-08-04 | Rhodes Jason P (President, CFO and Treasurer) | Sale | 30,000 | 29.66 | 889,650 |
| 2014-08-04 | Rhodes Jason P (President, CFO and Treasurer) | Option Ex | 42,000 | 2.07 | 86,940 |
| 2014-08-01 | Gould Robert J (CEO) | Sale | 30,000 | 30.37 | 911,190 |
| 2014-08-01 | Gould Robert J (CEO) | Option Ex | 30,000 | .51 | 15,300 |
| 2014-07-15 | Hedrick Eric (Chief Medical Officer) | Sale | 2,000 | 31.35 | 62,700 |
| 2014-07-15 | Hedrick Eric (Chief Medical Officer) | Option Ex | 2,000 | 2.19 | 4,380 |
| 2014-07-07 | Rhodes Jason P (President, CFO and Treasurer) | Sale | 30,000 | 33.03 | 990,990 |
| 2014-07-07 | Rhodes Jason P (President, CFO and Treasurer) | Option Ex | 42,000 | 1.55 | 65,100 |
| 2014-07-01 | Gould Robert J (CEO) | Sale | 30,000 | 31.71 | 951,180 |
| 2014-07-01 | Gould Robert J (CEO) | Option Ex | 30,000 | .51 | 15,300 |
| 2014-06-23 | Copeland Robert A (EVP and CSO) | Sale | 20,000 | 28.57 | 571,400 |
| 2014-06-23 | Copeland Robert A (EVP and CSO) | Option Ex | 20,000 | .56 | 11,100 |
| 2014-06-16 | Copeland Robert A (EVP and CSO) | Sale | 25,012 | 26.38 | 659,891 |
| 2014-06-16 | Hedrick Eric (Chief Medical Officer) | Sale | 2,000 | 26.42 | 52,840 |
| 2014-06-16 | Hedrick Eric (Chief Medical Officer) | Option Ex | 2,000 | 2.19 | 4,380 |
| 2014-06-02 | Gould Robert J (CEO) | Sale | 30,000 | 22.75 | 682,440 |
| 2014-06-02 | Gould Robert J (CEO) | Option Ex | 30,000 | .51 | 15,300 |
| 2014-06-02 | Copeland Robert A (EVP and CSO) | Sale | 38,400 | 22.71 | 872,102 |
| 2014-06-02 | Copeland Robert A (EVP and CSO) | Option Ex | 38,400 | .51 | 19,584 |
| 2014-06-02 | Rhodes Jason P (President, CFO and Treasurer) | Sale | 30,000 | 22.75 | 682,590 |
| 2014-06-02 | Rhodes Jason P (President, CFO and Treasurer) | Option Ex | 42,000 | 2.02 | 85,050 |
| 2014-05-19 | Copeland Robert A (EVP and CSO) | Sale | 5,000 | 22.28 | 111,380 |
Insider trading activities including stock purchases, stock sales, and option exercises of EPZM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Epizyme, Inc. (symbol EPZM, CIK number 1571498) see the Securities and Exchange Commission (SEC) website.